Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The approval makes this the first single-pill regimen containing dolutegravir available in a water-dispersible formulation.
A high-quality trial should improve access to dolutegravir for children worldwide.
Study shows just one snapshot of the impact of COVID-19 on the health and access to care among people living with HIV.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
People who switched to such a regimen gained up to 10 pounds in nine months.
The updates include new information on optimizing therapy, dealing with virological failure and managing opportunistic infections.
Many participants on two-drug regimens had more treatment under their belt and more chronic conditions.
A Brazilian man with HIV is no longer in remission after more than 15 months off treatment.
However, all integrase inhibitors were associated with similar weight gain.
The Department of Health and Human Services has updated its HIV treatment and prevention guidelines for pregnant people and their infants.
Compared with efavirenz-based regimens, dolutegravir-containing ones resulted in fewer switches and better viral control.
The São Paulo Patient is no longer HIV-free after more than 15 months off treatment, but was it a relapse or reinfection?
A 30-year retrospective review of abnormalities among infants born to women using antiretrovirals shows low, consistent levels.
Study results confirm that dolutegravir is a safe and effective treatment for pregnant women with HIV.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.